Paul R. Hansen - 18 Jan 2022 Form 4 Insider Report for Vyant Bio, Inc.

Role
Director
Signature
/s/ Andrew LaFrence, attorney-in-fact
Issuer symbol
N/A
Transactions as of
18 Jan 2022
Net transactions value
+$3,749
Form type
4
Filing time
20 Jan 2022, 20:19:52 UTC
Previous filing
27 Feb 2023
Next filing
01 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYNT Common Stock, $0.0001 par value Award $3,749 +2,862 +0.42% $1.31 685,720 18 Jan 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 18, 2022, the Reporting Person was granted 2,862 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2023, so long as Reporting Person remains a director though that date.
F2 Includes 64,901 shares previously held by a trust account which were transferred to the Reporting Person and are now held directly.